Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
- Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
- Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
- There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
- Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.